Cargando…

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials

Background: Many clinical trials with potential drug treatment options for non-alcoholic fatty liver disease (NAFLD) are focused on patients with non-alcoholic steatohepatitis (NASH) stages 2 and 3 fibrosis. As the histological features differentiating stage 1 (F1) from stage 2 (F2) NASH fibrosis ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leow, Wei-Qiang, Bedossa, Pierre, Liu, Feng, Wei, Lai, Lim, Kiat-Hon, Wan, Wei-Keat, Ren, Yayun, Chang, Jason Pik-Eu, Tan, Chee-Kiat, Wee, Aileen, Goh, George Boon-Bee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554942/ https://www.ncbi.nlm.nih.gov/pubmed/32872090 http://dx.doi.org/10.3390/diagnostics10090643

Ejemplares similares

Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence
por: Goh, George Boon-Bee, et al.
Publicado: (2019)

Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Chang, Pik Eu, et al.
Publicado: (2018)

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
por: Kumar, Rahul, et al.
Publicado: (2020)

Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients
por: Poh, Zhongxian, et al.
Publicado: (2015)

Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective
por: Li, James Weiquan, et al.
Publicado: (2017)

Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak “stable” patients on anti-HBV therapy
por: Sun, Yameng, et al.
Publicado: (2018)

Low serum albumin predicts early mortality in patients with severe hypoxic hepatitis
por: Chang, Pik-Eu, et al.
Publicado: (2017)

Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades
por: Goh, George Boon‐Bee, et al.
Publicado: (2017)

Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up
por: Lim, Chong Teik, et al.
Publicado: (2020)

Chronic Hepatitis E Infection Resulting in Graft Failure in a Liver Transplant Tourist
por: Tan, Hui-Hui, et al.
Publicado: (2011)

High-stakes examinations during the COVID-19 pandemic: to proceed or not to proceed, that is the question
por: Tan, Chee-Kiat, et al.
Publicado: (2021)

Epidemiology and Prognosis of Paraneoplastic Syndromes in Hepatocellular Carcinoma
por: Chang, Pik Eu, et al.
Publicado: (2013)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Liver Transplantation in an Adult with Citrullinaemia Type 2
por: Tan, Hui-Hui, et al.
Publicado: (2011)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Public awareness and knowledge of liver health and diseases in Singapore
por: Tan, Chee‐Kiat, et al.
Publicado: (2021)

CD30(+)OX40(+) Treg is associated with improved overall survival in colorectal cancer
por: Lam, Jian Hang, et al.
Publicado: (2021)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
por: Lee, Jin Ha, et al.
Publicado: (2020)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Acute Abdomen Secondary to Incarcerated Umbilical Hernia after Treatment of Massive Cirrhotic Ascites
por: Tan, Hiang Keat, et al.
Publicado: (2013)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b5e322j7k4dqbc40tlnlum4ve2